Some people with GLP-1 receptor polymorphisms respond beautifully to tirzepatide because the GIP receptor carries the metabolic load
Zepbound diarrhea is loose, watery, or frequent stools that occur as a side effect of Zepbound (tirzepatide), a once-weekly injectable for chronic weight management
Research dosing window: Typically studied in 46 week cycles in animal models
When osteoclast activity exceeds osteoblast (bone-building) activity the net result is loss of bone density.' Research supports this, as one trial found that taking semaglutide (one form of GLP-1) was associated with lower bone density and an increased rate of bone breakdown
Stopping semaglutides tends to lead to weight regain in many people, and studies have shown that a large portion of patients gain weight after stopping semaglutide
DOI.org (Crossref) , VCV000003597.87 ClinVar NCBI